<DOC>
	<DOCNO>NCT00504166</DOCNO>
	<brief_summary>The purpose study evaluate change bone structure determine magnetic resonance imaging measurement among early postmenopausal woman 24 month treatment alendronate , 70 mg week compare placebo</brief_summary>
	<brief_title>Alendronate Prevents Microarchitectural Deterioration Trabecular Bone Early Postmenopausal Women</brief_title>
	<detailed_description>This randomize , double-blind , 24-month study . Fifty-five postmenopausal woman , age range 45-65 year , low bone density recruit , half subject receive alendronate + 2800 IU vitamin D weekly , half receive placebo + 2800 IU vitamin D weekly . All study subject receive supplemental calcium 1000 mg/day + Vitamin D 400 IU/day . Measurements microarchitecture make wrist , ankle , hip , change trabecular bone assess 0 , 12 24 month . Markers bone turnover bone mineral density ( BMD ) use characterize cohort postmenopausal change bone turnover density .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>early postmenopausal woman 4565 year old Tscore range 1.1 2.5 either lumbar spine hip site exclusive Ward 's triangle least 3 vertebra rom L1L4 must evaluable Those high risk osteoporotic fracture within next 24 month , randomization placebo would unacceptable ( e.g. , prior history hip fracture , recent symptomatic clinical vertebral fracture , low BMD [ i.e. , BMD &gt; 2.5 SD young normal bone mass site exclusive Ward 's Triangle ] ) Current excessive tobacco use Abnormality esophagus delay esophageal empty , stricture achalasia Gastroesophageal reflux disease sufficient require regular medication Inability stand sit upright least 30 minute week Current use illicit drug history drug alcohol abuse within past 5 year Current alcohol use &gt; 3 drinks/day Any following : hypocalcemia ; severe malabsorption syndrome ; moderate severe hypertension uncontrolled ; new onset angina myocardial infarction within six month entry study ; evidence impair renal function define creatinine clearance &lt; 35 ml/min serum creatinine great 1.6 mg/dL ; organ transplantation ; significant end organ disease ( genitourinary , cardiovascular , endocrine , hepatic , psychiatric , renal , hematologic , pulmonary ) , opinion investigator , may pose added risk patient impair patient 's ability complete trial History evidence metabolic bone disease ( postmenopausal bone loss ) include limited vitamin D deficiency ( 25hydroxyvitamin D level &lt; 10 ng/ml ) , hypoparathyroidism , recent hyperthyroidism ( suppress TSH within six month prior entry study ) , Paget 's disease bone , Cushing 's disease , osteomalacia renal osteodystrophy History cancer . However , patient follow cancer consider eligible study : 1 ) superficial basal squamous cell carcinoma skin completely resect ; 2 ) malignancy completely treat without recurrence treatment last 5 year , follow exception : patient history breast cancer ( include histologic diagnosis lobular carcinoma situ ) , endometrial carcinoma , know suspect estrogensensitive neoplasia exclude regardless time since treatment disease status Any treatment bisphosphonate parathyroid hormone ; within last 6 month : estrogen , estrogen analogue ( e.g . raloxifene , tamoxifen ) tibolone anabolic steroid ; Estrogen take &gt; 3 month ago &lt; 1 week acceptable ; Topical ( vaginal ) estrogen cream ( &lt; 2 g ) use 2 time weekly acceptable ; Thyroid hormone , unless stable dose least six week randomization serum TSH within normal range ; Fluoride treatment dose great 1 mg/day 1 month time ; give short time one month must great 1 year randomization ; Glucocorticoid treatment one month &gt; 7.5 mg oral prednisone ( equivalent ) per day within six month prior randomization ; patient receive therapeutic glucocorticoid past must consider highly unlikely require retreatment dose oral glucocorticoid one month course study ; Treatment immunosuppressant ( e.g. , cyclosporine , azathioprine ) within previous year . Current expect treatment course study medication might alter bone calcium metabolism , include vitamin A excess 10,000 IU per day , vitamin D excess 5,000IU per day , calcitonin , phenytoin , heparin , lithium .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>